ALBUQUERQUE, N.M., Dec. 17 /PRNewswire-FirstCall/ -- The Board of
Directors of Protalex, Inc. (OTC Bulletin Board: PRTX) announced today their
selection of a new President and Chief Executive Officer, Mr. Steven H. Kane,
of New Hope, PA.
Kane comes to Protalex with over 23 years experience in the health care
industry. Most recently he was Vice President of North American Sales & Field
Operations for Aspect Medical. While at Aspect he guided the company through
12 quarters of successive growth resulting in a successful IPO in January
2000. Prior to Aspect, Kane was Eastern Area Vice President for Pyxis
Corporation, where he was instrumental in positioning the company for its
successful IPO in 1992. Pyxis later was acquired by Cardinal Health for
Of the Protalex opportunity, Kane said; "Protalex is a company that is on
the cutting edge of research and development in the treatment of a variety of
autoimmune diseases, most notably Rheumatoid Arthritis. I feel fortunate to
be joining a team that I consider to be of the highest caliber in the
industry, and I am confident that Protalex will evolve as the leader in the
emerging field of BioRegulation."
Board member and outgoing CEO, John E. Doherty added, "We are extremely
gratified that Steve has agreed to come on board at this critical time. His
skills and experience will be invaluable as the Company makes the transition
from development through regulatory approval to production and marketing of
our first BioRegulator drug for Rheumatoid Arthritis."
Statements in this press release that are not strictly historical are
"forward looking" statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements involve a high degree of risk and uncertainty, are
predictions only and actual events or results may differ materially from those
projected in such forward-looking statements. Factors that could cause or
contribute to differences include the Company's limited operating history,
uncertainty regarding viability and market acceptance of the Company's
products, and the Company's dependence on reimbursement by third parties.
These factors and others are more fully described in the section entitled
"Risks Related to the Company's Business" in the Company's Registration
Statement on Form 10-SB (File No. 00028385) as filed with the Securities and
MAKE YOUR OPINION COUNT - Click Here
SOURCE Protalex, Inc.